NCT05450705 is a Phase 3 clinical trial of 9vHPV vaccine in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT05450705?

NCT05450705 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT05450705?

Interventions in NCT05450705: 9vHPV vaccine.

What condition does NCT05450705 study?

NCT05450705 studies Papillomavirus Infections.

Is NCT05450705 still recruiting?

NCT05450705 is currently active, enrolled. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT05450705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

Active, enrolled Phase 3 Last updated 2 September 2022

What this trial tests

Phase 3 trial testing 9vHPV vaccine in Papillomavirus Infections in 1,500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 July 2022

Primary endpoint
3 August 2029

3 August 2029

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	1,500
Start date	22 July 2022
Primary completion	3 August 2029
Estimated completion	3 August 2029
Sites	2 locations across China

Drugs / interventions tested

9vHPV vaccine — full drug profile →

Conditions studied

Papillomavirus Infections — all drugs for Papillomavirus Infections →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

Adults 9 to 26, female only, with Papillomavirus Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to demonstrate that a 2-dose regimen of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) to each of the 9vHPV vaccine types in Chinese girls 9 through 14 years of age compared to a 3-dose regimen in Chinese women 20 through 26 years of age. The primary hypothesis is that a 2-dose regimen has a non-inferiority margin of 0.67 in the GMT ratio (girls vs. women) for each HPV type.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of 9vHPV vaccine

Trials testing the same drug.

NCT05314023 — Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) · Phase 3 · active not recruiting
NCT04772534 — Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) · Phase 3 · completed
NCT04708041 — Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) · Phase 3 · active not recruiting
NCT03546842 — Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males · Phase 3 · completed

Other recruiting trials for Papillomavirus Infections

Currently open trials in the same condition.

NCT05797246 — Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · Phase 2 · active not recruiting
NCT05285826 — Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) · Phase 3 · active not recruiting
NCT04724980 — Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis · Phase 1, PHASE2 · active not recruiting
NCT04708041 — Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) · Phase 3 · active not recruiting
NCT04199689 — Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHP · Phase 3 · active not recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05450705 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05450705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing